In Kentucky the Bluegrass Angels provide a pool of high-net-worth individuals, family offices, and investment funds with business experience who are looking for investment opportunities. Our members enjoy being involved with entrepreneurial ventures. The BGA provides a structured forum for such individuals to cooperatively source and vet deal flow. We would love to include you!…

Read More

The Bluegrass Angels, Inc. was founded in 2004 by local investors and community leaders who believed that early-stage investing could provide a meaningful return for investors while also spurring local economic growth. Individual members of the organization volunteer their time and expertise to review potential investments and assist entrepreneurs. BGA Venture Fund I raised $2…

Read More

With an investment from Bluegrass Angels, PowerTech Water is working to commercialize their breakthrough CapCo technology and other revolutionary water and wastewater treatment solutions. Engineered with PowerTech Water’s patent-pending Capacitive Coagulation technology, CapCo is an electrochemical filter that solves the problem of removing heavy metals from water. It uses activated carbon electrodes and small amounts…

Read More

Bluegrass Angels currently has over 70 active members in our organization who gather monthly to consider new business investment opportunities in the Commonwealth. Our members are committed to helping startups take their first steps by providing necessary capital in exchange for ownership equity or convertible debt in the company. If you are interesting in joining…

Read More

With an investment from the Bluegrass Angels, Thynk Health is on a mission to save lives by disrupting outdated, burdensome lung cancer screening processes without disrupting provider workflow. Their advanced solution automatically identifies and tracks patients from lung cancer screening through treatment to improve patient and program outcomes. Visit https://bit.ly/3cZBlWE to learn more. To see…

Read More

SAN DIEGO, May 20, 2020 /PRNewswire/ — Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary non-viral gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the first patient has been dosed in its Phase 1 clinical trial evaluating P-PSMA-101, its autologous CAR-T therapeutic…

Read More